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Abstract
Accurate prediction of survival of cancer patients is still a key open problem in clinical research. Recently, many large-scale
gene expression clusterings have identified sets of genes reportedly predictive of prognosis; however, those gene sets
shared few genes in common and were poorly validated using independent data. We have developed a systems biology-
based approach by using either combined gene sets and the protein interaction network (Method A) or the protein network
alone (Method B) to identify common prognostic genes based on microarray gene expression data of glioblastoma
multiforme and compared with differential gene expression clustering (Method C). Validations of prediction performance
show that the 23-prognostic gene classifier identified by Method A outperforms other gene classifiers identified by Methods
B and C or previously reported for gliomas on 17 of 20 independent sample cohorts across five tumor types. We also find
that among the 23 genes are 21 related to cellular proliferation and two related to response to stress/immune response. We
further find that the increased expression of the 21 genes and the decreased expression of the other two genes are
associated with poorer survival, which is supportive with the notion that cellular proliferation and immune response
contribute to a significant portion of predictive power of prognostic classifiers. Our results demonstrate that the systems
biology-based approach enables to identify common survival-associated genes.
Citation: Zhang J, Liu B, Jiang X, Zhao H, Fan M, et al. (2009) A Systems Biology-Based Gene Expression Classifier of Glioblastoma Predicts Survival with Solid
Tumors. PLoS ONE 4(7): e6274. doi:10.1371/journal.pone.0006274
Editor: Mark Isalan, Center for Genomic Regulation, Spain
Received April 9, 2009; Accepted June 15, 2009; Published July 17, 2009
Copyright:  2009 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partially supported by the Natural Science Foundation of China, Grant Nos. 30730035 30425004, and the National Key Basic Research
and Development Program (973), Grant No. 2007CB512304. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jiangtz@nlpr.ia.ac.cn (TJ); weisonyasong@gmail.com (SWS)
Introduction
The prediction of survival is critical when formulating a proper
treatment strategy for a patient with cancer. Clinicopathological
factors such as age, sex, and tumor grade are commonly used to
assess prognosis, but the prediction is limited. In glioma, tumor
grade is the most established predictor of disease outcome [1], but
patients with either grade III glioma or glioblastoma multiforme
(GBM), grade IV glioma, are nearly uniformly fatal [2–4]. The
subtle distinction of these two grades often misclassifies them into
either grade III glioma or GBM. Even histologically identical
tumors can behave in highly different manners from treatment
response to survival. Patients with GBM show remarkable
variations in survival from less than one week to more than three
years following diagnosis [5]. Thus, new prognostic classifiers are
urgently needed to more accurately predict the survival of
individual patients.
Microarray gene expression signatures have been reported to
predict survival of cancer patients [6]. However, sets of predictive
genes generated with the differential expression clustering share
few overlapping genes and exhibit less successful predictive power
in independent data [6]. The lack of agreement in prediction
raised doubts about the reliability and robustness of the reportedly
predictive genes. There are three major causes for the divergent
results: small groups of samples, complex nature of high-
throughput microarray technologies, and simplified analytical
methods in microarray data analysis. The use of small samples in
expression profiling makes it difficult to identify genes associated
with a condition or outcome, such as survival, from hundreds or
even thousands of genes that exhibit expression changes [6].
Highly variable microarray experimental conditions and the use of
different microarray platforms cause poor reproducibility of
microarray measurements within and between laboratories [7–
11]. Differential gene expression clustering (the SAM-based
analysis) is a common analytical tool used to analyze microarray
data. However, this method bases on only differential expression of
individual genes for target gene identification and ignores prior
knowledge of biological pathways that are composed of groups of
genes and interactions of their proteins, which is believed to be
more informative than expression changes of individual genes [7].
Several systematic approaches have been recently proposed to
address the problems. One approach uses a gene pathway-based
analysis, which identifies biological pathways (a priori defined gene
sets) by scoring the coherency of expression changes among their
member genes based on microarray data [7–9]. A gene set is an a
priori defined set of genes, in which genes share a similar biological
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allows biologists to incorporate previously accumulated biological
knowledge in the analysis and make a more biology-driven analysis
of microarray data, which can lead to identify interpretable
discriminative signature that gains insights into tumor biology and
potential therapeutic targets. In addition, this method enables to
identify moderately differentially expressed but functionally impor-
tant genes, which are missed in gene expression clustering [8]. The
method has been applied to discriminate irradiated from non-
irradiated yeast cells [9]. Another approach is a protein interaction
network-based method, which utilizes a recently available protein-
protein interaction network to identify sub-networks based on
coherent expression patterns of their genes [12,13]. A sub-network
refers to a smaller or more focused network within a large protein
interaction network. It has been applied to effectively differentiate a
metastatic from a non-metastatic breast tumor [10]. Both the
methods efficiently utilize co-expression information embedded
within the microarray gene expression data. However, the problem
of both the methods is that each gene set or sub-network identified
includes too many genes (,tens of genes each), which greatly limits
their clinical application.
Here, we develop asystems biology-based approach(MethodA)by
combining gene sets and the protein interaction network to identify
prognostic genes using microarray expression data of primary GBMs
and compare with other two methods, Method B, which uses the
protein interaction network alone, and Method C, which is based on
differential gene expression patterns. We find that the 23-prognostic
geneclassifier identified byMethod A predictsnot only the survivalof
glioma patients, but also the survival of patients with other solid
tumors such as breast cancer, lung cancer, bladder cancer, and
ovarian cancer, with the success on 17 of 20 independent sample
cohorts compared with 5–9 of 20 performed by the classifiers
identified by other two methods. We find that the 23-gene prediction
is independent of tumor grade and patient age, and 21 of the 23 genes
are associated with cell proliferation while the other 2 genes
associated with immune response, supporting the notion that cell
proliferation and immune response exhibit a significant prognostic
power. Our findings suggest that the 23-gene classifier may have
general utility in predicting survival for solid tumors.
Results
Prognostic Classifier Development Using Systematic and
Gene Expression Clustering Approaches for Primary GBM
To sufficiently utilize microarray expression data and the
recently available protein interaction network, we developed a
systems biology-based approach to identify prognostic gene
classifiers based on microarray expression data of primary GBMs
by using either combined gene sets and the protein interaction
network (Method A) or the protein interaction network alone
(Method B), and compared with conventional gene expression
clustering (the SAM-based analysis) (Method C) for prognostic
gene identification. The overall method strategy was outlined in
Figure 1 and Materials and methods.
We collected five advanced glioma data sets, two GBM sets
from the cohorts UCSF-1 (MD Anderson cancer center database)
[14] and UCSF-2 (Stanford microarray database) [15] and three
HGG (grade III and GBM combined) sets from the cohorts UCLA
(GEO GDS1975) [3], MDA (GEO GDS1815) [4], and CMBC
(BROAD institute database) [2] (Table 1). Among the five cohorts,
UCLA, UCSF-1 and MDA have 35, 34, and 49 primary GBMs
respectively, while CMBC and USCF-2 have only 14 and 15
primary GBMs, separately. Therefore, we used the three larger
primary GBM sets (UCSF-1, UCLA, and MDA) to train a
molecular classifier and left out the rest two GBM sets from
UCSF-2 and CMBC, and the three HGG cohorts for validation.
Considering experimental variations, different microarray plat-
forms used, and diverse patient populations existed among the
three training cohorts, we decided to apply the method (A, B, and
C) to each cohort independently and then reconciled candidate
prognostic genes from the three data sets to derive a final list of
prognostic genes based on their overlaps between any two cohorts
and concordant expression across the three cohorts with significant
expression in at least two cohorts.
Using the median OS as a cutoff for each cohort, we divided
microarray data of patients into short-term versus long-term
survival groups. By applying Method A, we identified 124, 114,
and 78 significantly enriched gene sets between the two survival
groups for UCSF-1, MDA, and UCLA, respectively (Tables S1,
S2, S3). From those enriched gene sets, 198, 257, and 164
candidate prognostic genes were identified for the three cohorts,
respectively, (for candidate prognostic genes and their scores,
please see Tables S4, S5, S6). Based on overlap between any two
cohorts and concordant expression across the three cohorts with
significant differential expression (P,0.05) in at least two cohorts,
we identified 23 prognostic genes (Table 2), from which ‘‘cyclin-
dependent kinase 2’’ (CDK2) and ‘‘interferon gamma receptor 1’’
(IFNGR1) were selected to demonstrate the null distribution of
their S values (Figure 2).
By using Method B, We obtained 147, 278, and 162
significantly enriched sub-networks between the two survival
groups for UCSF-1, UCLA, and MDA, respectively. From those
enriched sub-networks, we found 139, 131, and 133 candidate
prognostic genes for UCSF-1, MDA, and UCLA, respectively, (for
candidate prognostic genes and their scores, please see Tables S7,
S8, S9). Similarly, we identified 6 prognostic genes overlapped
between any two cohorts and concordantly expressed across the
three cohorts with significant differential expression (P,0.05) in at
least two cohorts (Table S10).
In Method C, we performed two-class analysis (students’ t test)
of microarray gene expression data to identify genes associated
with survival using the SAM software. We selected the same
number of top discriminative genes as the number of genes
identified by Method A for UCLA, UCSF-1, and MDA cohorts,
respectively, (Table S11, S12, S13). Similarly, we identified 11
prognostic genes overlapped between any two cohorts and
concordant expression across the three cohorts with significant
differential expression (P,0.05) in at least two cohorts (Table S14).
Validation of Classifier Performance in Advanced Gliomas
To compare prediction performance of the three prognostic
gene classifiers identified by Method A, B and C, we validated
them in the three training primary GBM cohorts (UCSF-1, MDA,
and UCLA), two independent GBM cohorts (CMBC and USCF-
2), and three HGG cohorts (UCLA, MDA, and CMBC). As shown
in Table 3, the multivariate Cox regression analysis indicated that
the 23-gene classifier found by Method A was independently and
significantly associated with survival in six of eight cohorts and
moderately in CMBC-HGG (HR=2.11; 95% CI, 1.03–4.35;
P=0.055), but not significantly in the training set UCLA.
Similarly, the 6-gene classifier by Method B had a significant
association with survival in six of the eight cohorts, but failed in the
training cohort UCLA and the validation cohort UCLA-HGG.
However, the 11-gene classifier by Method C was the worst
predictor, which failed in four of the eight cohorts, the training
cohort UCLA and three validation cohorts CMBC-GBM, UCLA-
HGG, and MDA-HGG. While all the three gene classifiers were
not predictive in the training cohort UCLA, the 23-gene signature
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assessed, followed by the 6-gene signature and then the 11-gene
signature in advanced gliomas.
Then, we compared the classification power of the three gene
classifiers. We generated Kaplan-Meier plots to illustrate survival
differences in the two survival groups for both the validation and the
Figure 1. Flowchart of Methods A, B and C. Schematic method overview of a systems biology-based approach using either combined gene sets
and the protein interaction network (Method A) or the protein interaction network alone (Method B) and conventional gene expression clustering
(the SAM-based analysis) (Method C) for prognostic gene identification based on microarray gene expression data of primary GBMs.
doi:10.1371/journal.pone.0006274.g001
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classified patients into two groups with distinctively different survival
time (Figure 3). Kaplan-Meier plots of the 6-gene and 11-gene
classifiers on all the cohorts were present in Figure S1, S2, S3, S4, S5,
S6. Alike the 23-gene classifier, the 6-gene classifier significantly
discriminated patients into two survival groups in all the cohorts
assessed, while the 11-gene classifier did not work well in two GBM
cohorts (UCLA and CMBC). The results indicate that the 23-gene
and 6-gene signatures are predictive of survival equally well on all the
eight advanced glioma cohorts, better than the 11-gene signature.
Validation of Classifier Performance in Other Tumor
Types
To assess the robustness of survival prediction of the three gene
classifiers for patients with other tumor types, we obtained 12
cohorts including five breast cancer cohorts: GIS (ArrayExpress E-
GEOD-3494) [16], CRCM (GEO GSE9893) [17], SUSM
(Stanford microarray database) [18], NCI (Rosetta inpharmatics
inc database) [19], EMC (GEO GSE2034) [20], five lung cancer
cohorts: DFCI (BROAD institute database) [21], PCH (GEO
GSE5843) [22], CAN/DF (caArray) [23], MSK (caArray) [23],
UM-HLM (caArray) [23], one bladder cancer cohort AUH (GEO
GSE5287) [24], and one ovarian cancer cohort MNI (GEO
GSE8842) with microarray expression data and clinicopathogical
information publicly available (detailed in Materials and methods)
(Table 1). According to the multivariate Cox regression analysis
(Table 4), we found that the 23-gene classifier achieved an
independent and significant association with survival in nine of the
12 cohorts, moderate in the cohort MSK (lung cancer)
(HR=2.29; 95% CI, 0.98–5.33; P=0.056), but not significant
in the two cohorts SUSM (breast cancer) and UM-HLM (lung
cancer). In contrast, the 6-gene and 11-gene classifiers were very
poorly associated with survival in those cohorts. They failed in ten
and nine of the 12 cohorts, respectively, and were only
significantly associated with survival in two cohorts: EMC (breast
cancer) and MNI (ovarian cancer), and three cohorts: CRCM
(breast cancer), EMC (breast cancer), and AUH (bladder cancer),
respectively. Altogether, the findings demonstrate that the 23-gene
classifier outperforms the other two gene classifiers in those tumor
types, supporting its validity of prognosis independent of tumor
grade or stage and patient age across solid tumor types.
We next examined the discriminative power of the 23-gene
classifier for survival by Kaplan-Meier analysis in all the 12
cohorts. It significantly classified patients into two different survival
groups on 11 of the 12 cohorts except for the cohort UM-HLM-
lung cancer (Figure 4A–D). For the four breast cancer cohorts that
had stages I, II, and III tumors combined (GIS, CRCM, SUSM
and EMC), we also used the 23-gene classifier to classify their
patients into three groups by hierarchical clustering, respectively,
and found that the three groups in each cohort were also
significantly associated with survival (P=0.0001, 0.0001, 0.0001,
and 0.01 for GIS, CRCM, SUSM and EMC, respectively).
Table 1. Summary statistics of cohort data.
Tumor type Cohort (Ref) Platform
Median
OS(m)
Age mean
(sd) (yr) Outcome
Tumor grade/stage
(sample size)
Training cohort
Primary GBM UCLA [3] Oligos Affymetrix 14 54 (15) 22
a IV (35)
c
MDA [4] Oligos Affymetrix 17.5 49 (12) 46
a IV (49)
c
UCSF-1 [14] Oligos Affymetrix 17 NA 34
a IV (34)
c
Validation cohort
GBM CMBC [2] Oligos Affymetrix 12 NA 24
a IV (28)
c
UCSF-2 [15] Spotted cDNA 10 62 (21) 15
a IV (20)
c
HGG (Grade III+GBM) UCLA [3] Oligos Affymetrix 15 46 (16) 48
a III (24); IV (50)
c
MDA [4] Oligos Affymetrix 23 46 (13) 62
a III (21); IV (55)
c
CMBC [2] Oligos Affymetrix 17 NA 33
a III (22); IV (28)
c
Breast GIS [16] Oligos Affymetrix 122 65 (14) 54
a I (62); II (121); III (51)
c
CRCM [17] Spotted Oligos 66 68 (10) 38
a I (21); II (94); III (33)
c
SUSM [18] Oligos Agilent 87 44 (6) 79
a I (75); II (101); III (119)
c
NCI [19] Oligos Rosetta inkjet 65 NA 34
b I (78)
c
EMC [20] Oligos Affymetrix 86 NA 107
b I+II+III (286)
c
Lung DFCI [21] Oligos Affymetrix 50 64 (11) 31
a I (49); II (13)
d
PCH [22] Spotted Oligos 53 63 (10) 23
a I (48)
d
CAN/DF [23] Oligos Affymetrix 40 61 (10) 28
a I (56); II (26)
d
MSK [23] Oligos Affymetrix 47 67 (9) 23
a I (63); II (20)
d
UM-HLM [23] Oligos Affymetrix 56 66 (10) 118
a I (160); II (48)
d
Bladder AUH [24] Oligos Affymetrix 13 NA 30
a III+IV (30)
c
Ovarium MNI(GSE8842) Spotted cDNA 80 52 (12) 13
a I (68)
d
aDeath.
bMetastasis.
cTumor grade.
dTumor stage. NA, not available. m, month. Yr, year. Ref, reference.
doi:10.1371/journal.pone.0006274.t001
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and Other Tumor Types
To assess the predictive power of previously published prognostic
gene signatures for advanced glioma in those cohorts, we tested
three main prognostic gene classifiers, 35-gene [4], 44-gene [3], and
47-gene [14] classifiers derived from MDA-HGG, UCLA-HGG,
and UCSF-1-GBM, respectively, on the 20 cohorts. To align with
the original reports, we divided patients into three (for 35-gene
classifier), four (for 44-gene classifier), and two(for 47-gene classifier)
groups accordingly. The multivariate Cox regression analysis
showed that the associations between the three gene classifiers
and survival were much poorer than the 23-gene classifier. The
hazard ratios for the 35-gene, 44-gene and 47-gene classifiers were
not statistically significant in four, two, and four of the eight
advanced glioma cohorts, separately, and eight, nine and 11 of the
12 other tumor cohorts, respectively (Table S15 and S16).
Moreover, we applied the fold-change of at least 1.5 and false
discovery rate cutoff of 10% to Method C for identification of
candidate prognostic genes for cohorts UCLA, UCSF-1 and
MDA, respectively. There was no overlapped prognostic gene
identified between any two cohorts. Moreover, we also performed
SAM survival analysis as an attempt to identify prognostic genes
for the same cohorts. 153 and 137 candidate prognostic genes
were identified for cohorts UCSF-1 and UCLA with false
discovery rate of 1% and 5%, respectively. For MDA, 59
candidate prognostic genes were found with a false discovery rate
of 25%. Based on overlap between any two cohorts and
concordant expression across the three cohorts with significant
differential expression in at least two cohorts, there was only one
gene, ‘‘leucine-rich repeats and immunoglobulin-like domains 1’’
(LRIG1), identified as prognostic gene marker. We also applied
univariate Cox regression analysis to Method A to calculate the
correlation (S) between expression activity and survival phenotype
for prognostic gene identification. As a result, we found 25
prognostic genes, which had 15 genes overlapped with the 23
genes (Table S17). Tests for prediction in all the 20 cohorts showed
that both the 25-gene and 15-gene classifiers had less prognostic
power than the 23 genes. They failed in three and four of the eight
glioma cohorts, separately, and six and nine of the 12 other tumor
cohorts, respectively, (Table S18 and S19).
In addition, we performed the gene set approach alone without
incorporating the protein interaction network, and identified
enriched prognostic gene sets shared in at least two data cohorts
with concordant expression (Table S20). Prediction tests showed
that the prognostic gene sets with a total of 576 genes had much
poorer prognostic power than the 23 genes, failed in 3 of 5 glioma
cohorts (Table S21).
Table 2. List of prognostic genes developed by method A
from primary GBM data of UCLA, USCF-1, and MDA.
Description
Gene
Symbol
Entrez
ID
minichromosome maintenance deficient 6 MCM6 4175
gamma 1 TUBG1 7283
thymidylate synthetase TYMS 7298
cyclin B1 CCNB1 891
WEE1 homolog (S. pombe) WEE1 7465
cyclin A2 CCNA2 890
CDC28 protein kinase regulatory subunit 1B CKS1B 1163
cyclin B2 CCNB2 9133
cell division cycle 7 homolog CDC7 8317
uracil-DNA glycosylase UNG 7374
replication protein A3, 14 kDa RPA3 6119
CDC6 cell division cycle 6 homolog (S. cerevisiae) CDC6 990
CDC45 cell division cycle 45-like (S. cerevisiae) CDC45L 8318
cyclin-dependent kinase 2 CDK2 1017
replication protein A2, 32 kDa RPA2 6118
ribonucleotide reductase M1 polypeptide RRM1 6240
DNA (cytosine-5-)-methyltransferase 1 DNMT1 1786
proliferating cell nuclear antigen PCNA 5111
ribonucleotide reductase M2 polypeptide RRM2 6241
pituitary tumor-transforming 1 PTTG1 9232
gamma-glutamyl hydrolase GGH 8836
ras-related C3 botulinum toxin substrate 2 RAC2 5880
interferon gamma receptor 1 IFNGR1 3459
doi:10.1371/journal.pone.0006274.t002
Figure 2. The null distributions of S values of CDK2 and IFNGR1. The null distribution of S values of CDK2 and IFNGR1 are computed from
MDA-GBM data. The left panel is the null distribution of S value of cell proliferation-related gene CDK2; the right panel is the null distribution of S
value of immune response-related gene IFNGR1.
doi:10.1371/journal.pone.0006274.g002
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Lists
To understand biological functions of the 23 prognostic genes,
we performed gene ontology analysis [25] (Table S22). We found
that 22 of the 23 genes were significantly associated with either
mitotic cell-cycle (EASE score, 1610
216), DNA metabolism
(EASE score, 6.27610
210), cell growth and/or maintenance (Ease
score, 0.00027), DNA repair (Ease score, 0.0052), or response to
stress/immune response (Ease score, 0.019). The only left-out gene
is GGH, which is involved in glutamine metabolism. Furthermore,
we found that poorer survival was associated with decreased
expression of two immune response-related genes, IFNGR1 and
‘‘ras-related C3 botulinum toxin substrate 2’’ (RAC2) and
increased expression of 21 genes related to cell cycle (15/23
genes), DNA metabolism (12/23) and repair (4/23), and cell
growth/maintenance (16/23), which is consistent with recent
reports showing that those biological functions are essential for
tumor progression and patient survival [26–29].
We then extracted a protein interaction sub-network based on
the 23 gene-encoded proteins and their interacting partners from
the human protein interaction network. Through GO annotation,
we found that the sub-network seeded by 23 genes was related to
some important functions, such as cell cycle, regulation of mitosis,
regulation of apoptosis, JAK-STAT cascase, MAPKKK cascade,
etc (Table S23). Furthermore, we found that most of the
interacting proteins were significantly enriched in the biological
functions related to cell proliferation and immune response. Those
proteins were highlighted in nodes of red (cell proliferation), green
(immune response), or half red and half green (both cell
proliferation and immune response) (Figure 5).
Finally, we examined the overlap of the 23 prognostic genes
with the other prognostic gene lists described above. We found
that the 23 genes shared only one gene, CDK2, with 6 genes and
11 genes, and no common gene was found with the additional
three glioma prognostic classifiers [3,4,14].
Discussion
The systematic integration of gene sets, the protein interaction
network, and microarray gene expression data offers us three main
advantages: First, it enables us to sufficiently utilize the gene co-
expression information provided by the microarray data, which is
believed to be more informative than expression changes of
individual genes for target gene identification. Second, identified
prognostic genes provide insights into the biology of tumor and
potential therapeutic targets. Third, it allows identifying common
survival-associated genes independent of tumor types.
The use of the gene sets (Method A) as pre-selected gene sources
may introduce some bias and miss an opportunity of finding new
survival-associated genes. In the study, we, therefore, directly
applied the microarray data to the protein interaction network to
first search for significantly enriched sub-networks as proposed by
Chuang et al [10], from which we identified prognostic genes
(Method B). We found that Method B produced a simpler classifier
made up of only 6 genes with 2 in common CDK2 and
‘‘replication protein A2’’ (RPA2) with the 23 genes, and performed
slightly less optimally to the 23-gene classifier in the eight glioma
cohorts, but very poorly in the 12 other tumor cohorts. This is not
surprising as reported by Boutros et al (PNAS 2009) that there
exist perhaps hundreds or even thousands of prognostic signatures
made up of a small count of genes in large and complex datasets
Table 3. Multivariate Cox regression analysis in training and validation cohorts of advanced gliomas.
Glioma Cohort Covariate 23 genes
a 6 genes
b 11 genes
c
P value HR (CI95%) P value HR (CI95%) P value HR (CI95%)
Training cohort
GBM UCLA cluster 0.131 1.96 (0.82–4.71) 0.095 2.48 (0.85–7.20) 0.590 1.30 (0.50–3.42)
age 0.001 1.06 (1.03–1.10) 0.007 1.05 (1.01–1.09) 0.001 1.06 (1.02–1.10)
UCSF-1 cluster 0.005 3.19 (1.43–7.13) 0.001 4.22 (1.88–9.45) 0.005 2.95 (1.39–6.27)
MDA cluster 0.013 2.29 (1.19–4.41) 0.034 1.94 (1.05–3.59) ,0.0001 3.16 (1.66–6.01)
age 0.522 1.01 (0.98–1.04) 0.905 1.00 (0.97–1.03) 0.761 1.01 (0.97–1.02)
Validation cohort
GBM CMBC cluster 0.012 3.05 (1.27–7.30) 0.03 2.73 (1.11–6.76) 0.074 2.37 (0.92,6.12)
UCSF-2 cluster 0.037 4.24 (1.09–16.52) 0.045 3.77 (1.03–13.83) 0.04 4.05 (1.21–13.49)
age 0.09 1.04 (0.99–1.09) 0.069 1.05 (1.00–1.10) 0.055 1.05 (1.00–1.11)
HGG (Grade III+GBM) UCLA cluster 0.037 1.94 (1.04–3.60) 0.417 1.30 (0.70–2.43) 0.879 1.05 (0.54–2.04)
grade 0.011 2.84 (1.27–6.35) 0.003 3.27 (1.48–7.20) 0.004 3.31 (1.46–7.05)
age 0.217 1.01 (0.99–1.04) 0.209 1.01 (0.99–1.04) 0.151 1.02 (0.99–1.04)
MDA cluster 0.005 2.09 (1.25–3.49) 0.014 1.96 (1.15–3.34) 0.268 1.49 (0.74–3.00)
grade 0.015 2.54 (1.20–5.38) 0.01 2.63 (1.26–5.06) 0.077 2.14 (0.92–4.95)
age 0.142 1.02 (0.99–1.04) 0.184 1.02 (0.99–1.04) 0.248 1.01 (0.99–1.04)
CMBC cluster 0.055 2.11 (1.03–4.35) 0.001 2.84 (1.34–5.98) 0.028 2.71 (1.11–6.57)
grade 0.01 2.66 (1.26–5.63) 0.045 2.20 (1.02–4.74) 0.36 1.54 (0.61–3.91)
*The direction of the hazard ratio is as follows: cluster, the short-term versus long-term survival group; grade, GBM versus grade III; age, older versus younger.
aMethod A.
bMethod B.
cMethod C.
doi:10.1371/journal.pone.0006274.t003
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solid tumors and its potential generality shared among the solid
tumors. Moreover, we did not find any new prognostic genes using
Method B. Compared with those two gene classifiers, the 11-gene
classifier found by Method C (the SAM-based analysis) was
obviously incapable of predicting survival in advanced glioma and
other tumor types tested, suggesting that the systematic approach
with the gene set scale is powerful over gene expression clustering
for prognostic gene identification.
When searching for a consensus prognostic gene classifier, some
studies have applied a combined (meta-) analysis of several
microarray expression data sets and used certain mathematical
methods such as Singular value decompositions (SVDs) [31,32],
distance-weighted discrimination (DWD) [33,34] or analysis of
variance (ANOVA) [35] to ‘‘correct’’ systematic biases existed
among those data sets to train classifiers [34,36]. While these
methods are certainly a step forward in the right direction, they
may bring in some problems as well. Experimental biases present
in similar data sets generated in different laboratories using
different microarray platforms can be possibly lessened or
removed by those methods. However, if data sets contain diverse
patient populations, technical and biological effects embedded in
the microarray data can not be differentiated. Thus, when
applying those methods to ‘correct’ such microarray data,
informative biological variability will be removed as well.
In our study, the three training cohorts had very diverse patient
populations from the median OS of 14 months (ranged 2–44.54
months) (UCLA), 17 months (0.65–114.85 months) with 17.6% of
patients having OS .45 months (UCSF-1) to 17.5 months (0.75–
78.25 months) with 18.4% of patients having OS .45 months
(MDA). Therefore, we think that it is more reasonable to apply the
method (A, B, and C) to each cohort and then reconcilethe candidate
Figure 3. Kaplan-Meier plots of overall survival for advanced gliomas generated by the 23-gene classifier. (A) Two GBM cohorts UCSF-2
and CMBC. (B) Three HGG cohorts MDA, UCLA, and CMBC. (C) Three GBM training cohorts MDA, UCLA, and UCSF-1. STS, short-term survival group;
LTS, long-term survival group. N, the number of patients within STS or LTS group. P values are indicated within plots. P,=0.05 is defined as
significance.
doi:10.1371/journal.pone.0006274.g003
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based on their overlaps among any two cohorts and concordant
expressionacrossthethreecohorts.WenoticethatUCLAhasamore
biased population with a shorter survival. It may explain why it is
difficult to classify the UCLA patients into survival-associated clusters
independent of tumor grade and patient age.
Validation of the 23 genes in 20 independent and heteroge-
neous sample cohorts presented here illustrates the predictive
power of the 23-gene classifier independent of tumor grade and
patient age across several tumor types. It performs well in either
uniform or combined low- or high-grade tumors, indicating that
the 23 gene-associated functions (cellular proliferation and
immune response) are fundamental and essential for prognosis
with both low- and high-grade solid tumors, in other words,
cellular proliferation and immune response may be two key
prognostic components shared by solid tumors, which is supported
by recent findings in breast cancer and lung cancer [26–28]. This
may explain why the 23-gene classifier performs well in those
tumor cohorts tested in this study.
The power of this approach is presently limited by the number
of genes in gene pathways and the protein interaction network;
however, the prediction performance of the 23-gene signature is
impressive, given that only ,35% of genes are matched in the
annotation between our gene sets and the Affymetrix platforms.
Future studies will be required to validate the prognostic power of
the 23-gene classifier across additional, different tumor types.
We conclude that the systematic approach enables us to identify
23-prognsotic gene classifier that is the first to be valid in 17/20
independent tumor cohorts across several tumor types, suggesting
their commonality for solid tumors, especially, for highly
proliferating tumors. This approach may also prove useful for
other purposes such as for therapeutic response and metastasis.
Materials and Methods
Data Collection
We collected microarray gene expression data and clinicopath-
ological information for patients with advanced glioma from three
Table 4. Multivariate Cox regression analysis in validation cohorts of other tumor types.
Tumor type Cohort Covariate 23 genes
a 6 genes
b 11 genes
c
P value HR (CI 95%) P value HR (CI 95%) P value HR (CI 95%)
Breast GIS cluster 0.003 2.37 (1.34–4.18) 0.267 1.41 (0.77–2.58) 0.42 1.27 (0.71–2.28)
grade 0.015 1.69 (1.11–2.57) 0.003 1.89 (1.24–2.88) 0.002 1.93 (1.27–2.95)
age 0.758 1.00 (0.98–1.02) 0.887 1.00 (0.98–1.02) 0.808 1.00 (0.98–1.02)
CRCM cluster ,0.0001 5.51 (2.66–11.41) 0.079 1.82 (0.93–3.54) ,0.0001 5.10 (2.46–10.57)
grade ,0.0001 4.41 (2.37–8.22) ,0.0001 3.27 (1.85–5.81) ,0.0001 4.18 (2.27–7.71)
age 0.688 0.99 (0.96–1.03) 0.757 1.00 (0.96–1.03) 0.751 0.99 (0.96–1.03)
SUSM cluster 0.08 1.60 (0.95–2.69) 0.396 1.26 (0.76–2.07) 0.955 1.01 (0.65–1.58)
grade 0.001 2.35 (1.63–3.40) ,0.0001 2.56 (1.80–3.65) ,0.0001 2.59 (1.82–3.68)
age 0.03 0.96 (0.92–1.00) 0.034 0.96 (0.92–1.00) 0.024 0.96 (0.92–0.99)
NCI cluster 0.014 4.40 (1.34–14.41) 0.324 1.41 (0.71–2.77) 0.336 1.42 (0.69–2.92)
EMC cluster 0.006 1.71 (1.17–2.51) 0.022 1.59 (1.07–2.37) 0.004 1.74 (1.19–2.56)
Lung DFCI cluster 0.012 2.53 (1.23–5.24) 0.299 1.48 (0.71–3.07) 0.162 1.71 (0.81–3.62)
stage 0.167 1.76 (0.79–3.91) 0.129 1.86 (0.84–4.14) 0.211 1.69 (0.74–3.84)
age 0.091 1.03 (1.00–1.07) 0.125 1.03 (0.99–1.08) 0.154 1.03 (0.99–1.07)
PCH cluster 0.039 2.44 (1.04–5.68) 0.15 1.85 (0.80–4.27) 0.145 1.89 (0.80–4.45)
age 0.216 1.03 (1.00–1.07) 0.288 1.02 (0.98–1.07) 0.202 1.03 (0.99–1.07)
CAN/DF cluster 0.044 2.08 (1.02–4.25) 0.208 1.63 (0.76–3.48) 0.775 1.11 (0.55–2.24)
stage 0.007 2.54 (1.29–4.99) 0.016 2.42 (1.18–4.96) 0.003 2.79 (1.41–5.52)
age 0.001 1.08 (1.04–1.14) 0.001 1.08 (1.03–1.14) 0.002 1.07 (1.03–1.12)
MSK cluster 0.056 2.29 (0.98–5.33) 0.278 1.64 (0.67–3.99) 0.072 2.19 (0.93–5.13)
stage 0.219 1.77 (0.71–4.40) 0.105 2.19 (0.85–5.65) 0.189 1.84 (0.74–4.55)
age 0.44 1.02 (0.97–1.07) 0.346 1.02 (0.98–1.07) 0.534 1.02 (0.97–1.06)
UM-HLM cluster 0.461 1.15 (0.80–1.66) 0.519 1.13 (0.78–1.65) 0.759 1.06 (0.72–1.59)
stage ,0.0001 2.28 (1.54–3.37) ,0.0001 2.32 (1.57–3.44) ,0.0001 2.31 (1.56–3.41)
age 1 1.03 (1.01–1.05) 0.002 1.03 (1.01–1.05) 0.002 1.03 (1.01–1.05)
Bladder AUH cluster 0.035 2.31 (1.06–5.02) 0.284 1.53 (0.70–3.31) 0.026 2.44 (1.11–5.35)
Ovarium MNI cluster 0.016 4.02 (1.30–12.40) 0.002 8.01 (2.12–30.27) 0.219 2.02 (0.66–6.17)
age 0.094 1.06 (0.99–1.13) 0.035 1.08 (1.01–1.16) 0.069 1.06 (1.00–1.12)
*The direction of the hazard ratio is as follows: cluster, the short-term versus long-term survival group; grade, lower versus higher; age, older versus younger.
aMethod A.
bMethod B.
cMethod C.
doi:10.1371/journal.pone.0006274.t004
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PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6274Figure 4. Kaplan-Meier plots of overall survival for other solid tumor types generated by the 23-gene classifier. (A) Five lung cancer
cohorts DFCI, PCH, CAN/DF, MSK, and UM-HLM. (B) Five breast cancer cohorts GIS, CRCM, SUSM, NCI and EMC. For NCI and EMC, the overall survival
times were unavailable and thus time to distant metastasis for prediction was used instead. (C) One bladder cancer cohort AUH. (D) One ovarian
cancer cohort MNI. STS, short-term survival group; LTS, long-term survival group. N, the number of patients within STS or LTS group. P values are
indicated within plots. P,=0.05 is defined as significance.
doi:10.1371/journal.pone.0006274.g004
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two GBM data sets publicly available: 74 samples of HGG from
UCLA [3], 76 samples of HGG from MDA [4], 50 samples of
HGG from CMBC [2], 34 samples of primary GBM from UCSF-
1 [14] and 20 samples of GBMs (primary and secondary GBMs
combined) from UCSF-2 [15]. We used 118 samples of primary
GBM (34 from UCSF-1, 35 from UCLA, and 49 from MDA) as a
training set for prognostic gene identification and two independent
GBM sample sets from CMBC and UCSF-2 and the three HGG
sets from UCLA, MDA, and CMBC for validation. To test the
robustness of identified prognostic gene classifiers in different
tumor types, we collected 12 completely independent data sets
from four different tumor types: five lung cancer sets including 62
stages I-II lung adenocarcinomas from DFCI [21], 48 stage I lung
tumors from PCH [22], 82 stages I–II lung adenocarcinomas from
CAN/DF [23], 83 stages I–II lung adenocarcinomas from MSK
[23], and 208 stages I–II lung adenocarcinomas from UM-HLM
[23]; five breast cancer sets including 236 grades I–III breast
cancers from GIS [16], 155 grades I–III breast cancers from
CRCM [17], 295 grades I–III breast cancers from SUSM [18], 78
stage I breast cancers from NCI [19], and 286 lymph-node-
negative breast cancers (mainly stage I) from EMC [20]; one
bladder cancer set of 30 advanced bladder cancers from AUH
[24]; one ovarian tumor set of 68 stage I ovarian carcinomas from
MNI (GEO GSE8842). For the two breast cancer cohorts NCI
and EMC, where the overall survival times were unavailable, time
to distant metastasis was used instead. For all the cohorts, we used
normalized microarray data which are available in public domain
(see references). Because several different microarray platforms
were used in those cohorts, we ensured that the probes were
matched to identical genes. Microarray expression data of
prognostic genes identified in this study were further normalized
into Z scores prior to clustering. Summary statistics of cohort data
sets were presented in Table 1.
Method A
To integrate gene sets, canonical biological pathways (439
pathways total) were first extracted from the public pathway
database MsigDB (http://www.broad.mit.edu/gsea/msigdb/)
[37,38] and then combined with ten human-focused cancer-
associated pathways from the Cancer Cell Map (http://cancer.
cellmap.org) to form the biggest gene pathways of a total of 449
canonical pathways up to the current date. Further, 2,128 cancer-
associated genes [39] were extracted and classified into 403
functional categories using Gene Ontology Consortium analysis
(http://www.geneontology.org). After removing overlapped genes
between the two gene sources, our 852 gene sets contained 449
gene pathways and 403 functional categories with a total of 5,049
Figure 5. The protein interaction sub-network based on 23 prognostic gene-encoded proteins and their interacting partners. Nodes
represent gene-encoded proteins; links represent physical interactions. Nodes in color indicate enriched biological functions of the proteins. Red
nodes represent cell proliferation, green nodes represent immune response, and half red and half green nodes represent both cell proliferation and
immune response. Proteins in a bigger circle represent the 23 gene-encoded proteins; their interactions with partners with enriched biological
functions are highlighted in blue links, whereas grey links represent interactions of the 23 gene-encoded proteins with other partners (white circle).
doi:10.1371/journal.pone.0006274.g005
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set that shows statistically significant differences between short-
term and long-term survival groups identified by gene set
enrichment analysis. Significantly enriched gene sets were then
identified by performing gene set enrichment analysis (measuring
the degree of differential gene expression in a gene set) between
two distinctive survival groups based on microarray expression
data using SAM-GS software [8].
Significantly enriched gene sets were next mapped to the
human protein-protein interaction network that has 9,213 genes
and 37,107 interactions [40] to obtain an enriched gene sub-
network. Survival-associated genes were identified by sequentially
scoring the genes in the enriched sub-network. Specifically, given a
gene G, let E represent its vector of expression scores over tumor
samples, and let T represent the corresponding vector of survival
phenotype. To derive E, the expression values of gene G and its
nearest neighbor genes in the enriched sub-network were
normalized over all samples (mean=0; s.d.=1). The normalized
expression values of gene G and its neighbor genes were averaged
into a combined score, designated as E. The correlation between E
and T, denoted as S, was calculated by Pearson correlation
analysis. The null distribution of S was estimated by permuting the
survival phenotype 100,000 times. The final score of gene G was
indexed on this null distribution. Because the Bonferroni
correction used to adjust for multiple comparisons is often too
concervative when applied to microarray data [41], the less
stringent Benjamini and Hochberg false discovery rate [42] was
performed for multiple comparison correction. A significant
survival-associated gene was identified when the corrected P value
of the correlation was less than 0.05.
Method B
Method B was divided into two steps. The first was to identify
significantly enriched sub-networks using microarray gene expres-
sion data and the protein interaction network as described by
Chuang et al [10]. Briefly, expression values of genes from
microarray expression analysis were directly overlaid on their
corresponding proteins in the protein interaction network (7,683
genes from the training sets UCLA and MDA and 6046 genes
from the training set UCSF-1) to search for enriched sub-networks
by calculating the discriminative score (student’s t test) of the
relationship between expression activity of each sub-network and
survival phenotype. Sub-network started from a seed protein and
iteratively expanded by adding a protein from the neighbors of the
seed protein until no addition increased the discriminative score.
The significance of the discriminative score was estimated by
permuting survival phenotype 100,000 times. The final score of
sub-network was indexed on this null distribution. A significantly
enriched (differentially expressed) sub-network was identified when
the P value of relationship was less than 0.05.
Secondly, to identify survival-associated genes from significantly
enriched sub-networks, an expression value of each gene in the
enriched sub-networks was z-transformed over all samples and the
association between its z-transformed value and survival was then
assessed by univariate Cox regression analysis. The less stringent
Benjamini and Hochberg false discovery rate [42] was performed
for multiple comparison correction. A prognostic gene was
identified when the corrected P value of the association was less
than 0.05.
Method C
Differentially expressed genes between two distinctive survival
groups were directly identified by two-class analysis (students’ t
test) of microarray gene expression data using the SAM software.
SAM output data were presented along with the false discovery
rate. The same number of top discriminative genes was selected as
the number of genes identified by method A while, where possible,
the lowest false discovery rate was adopted.
Survival Prediction
Multivariate Cox proportional-hazards regression analysis with
stepwise selection was used to evaluate independent prognostic
factors associated with survival, and gene expression cluster
defined by gene classifier (or subsets of gene classifier), tumor
grade or stage, and age were used as covariates. For each
covariate, a hazard ratio and an associated P value were
examined. The Kaplan-Meier method was used to estimate
overall survival distribution and metastasis-free survival distribu-
tion (for two breast cancer cohorts). Differences in survival
between distinctive survival groups were analyzed with the log-
rank test. A P value of less than 0.05 was considered to indicate
statistical significance, and all tests were two-tailed. Statistical
analyses were carried out using SPSS software version 13.
As for testing three glioma prognostic gene classifiers reported
previously [3,4,14], the 35-gene, 44-gene and 47-gene classifiers
divided patients into three, four and two prognostic groups,
respectively, in our cohorts to be consistent with their original
studies.
Gene Ontology Analysis
Gene functions and their biological significance (EASE score)
were assessed by using the EASE annotation tool (EASE software
version 2.0) [25]. Fisher’s exact test combined with Bonferroni
correction was used to calculate the significance.
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